Compare WGO & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WGO | NGNE |
|---|---|---|
| Founded | 1958 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.0M | 744.9M |
| IPO Year | 1994 | 2014 |
| Metric | WGO | NGNE |
|---|---|---|
| Price | $31.32 | $25.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | $35.57 | ★ $77.88 |
| AVG Volume (30 Days) | ★ 930.7K | 342.8K |
| Earning Date | 12-18-2026 | 11-20-2026 |
| Dividend Yield | ★ 4.34% | N/A |
| EPS Growth | ★ 32.97 | 0.93 |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $1,985,674,000.00 | N/A |
| Revenue This Year | $0.00 | N/A |
| Revenue Next Year | $5.17 | N/A |
| P/E Ratio | $28.17 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.95 | $15.93 |
| 52 Week High | $50.16 | $43.66 |
| Indicator | WGO | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 60.16 | 47.84 |
| Support Level | $27.54 | $24.88 |
| Resistance Level | $31.79 | $28.47 |
| Average True Range (ATR) | 1.76 | 2.50 |
| MACD | 0.68 | 0.38 |
| Stochastic Oscillator | 71.53 | 35.88 |
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2010 with the acquisition of SunnyBrook and acquired Grand Design in 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in 2019, and acquired Barletta pontoon boats in 2021. It also is developing electric and autonomous technology.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.